• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    2/18/26 4:05:08 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    6-K 1 pavs_6k.htm FORM 6-K pavs_6k.htm

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2026

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LIMITED

    (Exact name of registrant as specified in its charter)

     

    250 Park Avenue, 7th Floor

    New York, NY 10017

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form40-F.

     

    Form 20-F  ☒      Form 40-F  ☐

     

     

     

     

    Submission of Matters to a Vote of Security Holders.

     

    Paranovus Entertainment Technology Limited (the “Company”) held an extraordinary meeting of shareholders (“EGM”) at 10:00 a.m. EDT on February 18, 2026 at its principal executive offices in 250 Park Avenue, 7th Floor, New York, NY 10017. Shareholders of Class A and Class B ordinary shares voted by proxy or at the meeting. There were shareholders of 57.53% out of a total votes of 3,500,032 Class A ordinary shares (representing  3,500,032 votes) and 46,123 Class B ordinary shares (representing 3,689,840 votes) and therefore constituting a quorum of more than one third of the shares outstanding and entitled to vote at the meeting as of the record date of January 21, 2026. Each Class A ordinary share is entitled to one vote, and each Class B ordinary share is entitled to eighty (80) votes. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

    1.

    that the following constitutes the number of shares voted with respect to the special resolution of the shareholders to approve, to reduce the share capital of the Company (the “Capital Reduction”), supported by a solvency statement in accordance with sections 14A and 14B of the Companies Act (as revised) of the Cayman Islands from:

     

    (a) US$3,351,500,000 divided into 3,350,000,000 Class A ordinary shares of US $1.00 par value each and 1,000,000 Class B ordinary shares of a par value of US $1.00 each, and 500,000 preferred shares of a par value of US $1.00 each,

     

    to:

     

    (b) US$3,351.5 divided into 3,350,000,000 Class A ordinary shares of US $0.000001 par value each and 1,000,000 Class B ordinary shares of a par value of US $0.000001 each, and 500,000 preferred shares of a par value of US $0.000001 each, 

     

    by the Company effecting a share capital reduction to the par value of each authorised (including issued and unissued) share, at a ratio of one million-to-one, with no cancellation or redemption of shares, no alteration to the number of shares in issue, no return of capital to shareholders and no extinguishment or reduction of any unpaid liability in respect of any shares, such that the par value of each authorized (including issued and unissued) share forming the Company’s share capital is decreased from US $1.00 to US $0.00001, having the rights and being subject to the restrictions set out in the Sixth Amended and Restated Memorandum of Association of the Company (the “Capital Reduction Proposal”);

     

    For

     

    Against

     

    Abstain

    4,035,110

    95,272

    6,240

     

     

    Accordingly, the Capital Reduction Proposal has been approved.

     

     

    2.

    That the following constitutes the votes with respect to the ordinary resolution of the shareholders to approve to further increase the share capital of the Company (the “Capital Increase”) from:

     

    (i) US$3,351.5 divided into 3,350,000,000 Class A ordinary shares of US$0.000001 par value each and 1,000,000 Class B ordinary shares of a par value of US $0.000001 each, and 500,000 preferred shares of a par value of US $0.000001 each,

     

    to:

     

    (ii) US$3,400.5 divided into 3,350,000,000 Class A ordinary shares of US$0.000001 par value each and 50,000,000 Class B ordinary shares of a par value of US $0.000001 each, and 500,000 preferred shares of a par value of US $0.000001 each,

     

    by creating an additional number of Class B ordinary shares, in amount of 49,000,000 Class B ordinary shares, each with a par value of US $0.000001 (the “Capital Increase Proposal”):

     

    For

     

    Against

     

    Abstain

    3,732,419

    86,475

    555

      

     

    Accordingly, the Capital Increase Proposal has been approved. 

     

     

    3.

    that the following constitutes the number of shares voted with respect to the ordinary resolution of the shareholders to approve to amend and restate in full the residual prior shareholders’ resolution adopted in the extraordinary general meeting held on November 26, 2025, so that, following implementation of such revised approval, the board of directors will be authorized to amend the Company’s authorized share capital by way of a consolidation (“Share Consolidation”) at an aggregate exchange ratio of up to one-for-five thousand (1:5,000) such that the number of authorized, issued and outstanding shares is decreased by the applicable ratio and the par value of each authorized, issued and outstanding ordinary share is increased by the same ratio, as applicable, with each Share Consolidation to be effected at such time or times, and at the precise consolidation ratio or ratios in each case as determined by the Directors in their absolute discretion within two (2) years following the date of the 2026 Extraordinary Meeting (the “Share Consolidation Proposal”):

     

    For

     

    Against

     

    Abstain

    4,003,437

     

    130,051

     

    3,134

     

     

    Accordingly, the Share Consolidation Proposal has been approved.  

     

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Paranovus Entertainment Technology Limited

     

     

     

     

     

    Date: February 18, 2026

    By:

    /s/ Xiaoyue Zhang

     

     

     

    Xiaoyue Zhang

    Chief Executive Officer

     

     

     

    3

     

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    2/18/26 4:05:08 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    1/22/26 5:25:13 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    1/13/26 4:15:52 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care